*
Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice
543210
Explain elements of creating a new system for cancer research and management.
Integrate key factors in the value proposition into the implementation of cancer care programs.
Describe how clinical pathways are integral to the creation of a symmetrical health care system.
Explain the physical and biological characteristics of radiation therapy technology for oncologic use, with an emphasis on the characteristics of proton beam therapy.
Recognize the challenges underlying technology testing paradigms in radiation oncology in general, and proton therapy in particular, in the limited structure of existing clinical trials design strategies.
Appreciate the potential for application of advanced radiation modalities such as proton therapy in several oncologic scenarios.
Differentiate the approximate proportion of all cancers that are associated with inherited predisposition.
Recognize certain more common hereditary cancer syndromes.
Appreciate the role of genetic counseling in prevention of cancer in high-risk individuals.
Outline various strategies for reducing the risk of genetic predisposition for some cancers.
Explain and discuss how mechanistic and translational research over the last few years has changed patients’ outcomes and the practice of oncology today.
Discuss the concept of driver mutations in cancer, which ones are actionable by virtue of targeted drug availability and which ones clinical research is currently focused on.
Appraise the current status of immunotherapy and the promise of this field for the future.
Describe the unique role of the research nurses in clinical trial delivery.
Discuss methods for integrating research nurses into the multidisciplinary research team.
Describe the role of research nursing in optimizing matching of appropriate patients to early phase clinical trials.
*
Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.
54321
Derek Raghavan, MD PhD FACP FRACP FASCO - Keynote: The Challenge of a Clean Slate
Miguel Villalona-Calero, M.D. - Molecular Targeted Therapy and Immunotherapy
Jeffrey Boyd, Ph.D. - Genetic Predisposition in Cancer
Minesh Mehta, MD, FASTRO - Innovations in Radiation Oncology
Dorothy Dulko, Ph.D., RN, NP-C - The Role of Research Nursing in the Multidisciplinary Delivery of Quality Clinical Trials
*
*
*
*
*
*
*
*
*
*